C. McNeil

发表

Herceptin raises its sights beyond advanced breast cancer.

C. McNeil, 1998, Journal of the National Cancer Institute.

NCI-MATCH launch highlights new trial design in precision-medicine era.

Caroline McNeil, C. McNeil, 2015, Journal of the National Cancer Institute.

Breast cancer decline mirrors fall in hormone use, spurs both debate and research.

C. McNeil, 2007, Journal of the National Cancer Institute.

HPV in oropharyngeal cancers: new data inspire hope for vaccines.

C. McNeil, 2000, Journal of the National Cancer Institute.

Consensus panel on cervical cancer highlights the HPV connection.

C. McNeil, 1996, Journal of the National Cancer Institute.

Who invented the VLP cervical cancer vaccines?

C. McNeil, 2006, Journal of the National Cancer Institute.

Cancer fatigue: one drug fails but more are in the pipeline.

C. McNeil, 2001, Journal of the National Cancer Institute.

Using HER2 to choose chemotherapy in breast cancer: is it ready for the clinic?

C. McNeil, 1999, Journal of the National Cancer Institute.

Herceptin in the adjuvant setting: phase III trials begin.

C. McNeil, 2000, Journal of the National Cancer Institute.

HIV infection with Hodgkin's disease: the virus makes a difference.

C. McNeil, 1997, Journal of the National Cancer Institute.

Human papillomavirus and oral cancer: looking toward the clinic.

C. McNeil, 2008, Journal of the National Cancer Institute.

K-Ras mutations are changing practice in advanced colorectal cancer.

C. McNeil, 2008, Journal of the National Cancer Institute.

The depression of T lymphocytes after trauma.

C. McNeil, A. R. Bauer, J. D. Mason, 1978, American journal of surgery.

New standard of care for cervical cancer sets stage for next questions.

C. McNeil, 1999, Journal of the National Cancer Institute.

Geriatric oncology clinics on the rise.

C. McNeil, 2013, Journal of the National Cancer Institute.

A new generation of monoclonal antibodies arrives at the clinic.

C. McNeil, 1995, Journal of the National Cancer Institute.

How should HER2 status be determined?

C. McNeil, 1999, Journal of the National Cancer Institute.

Topotecan: after FDA and ASCO, what's next?

C McNeil, C. McNeil, 1996 .

Monoclonal Antibodies to Watch

C. McNeil, 1995 .

Micrometastases matter in new melanoma staging system.

C. McNeil, 2000, Journal of the National Cancer Institute.

Can guidelines be integrated into everyday practice? The NCCN in year 4. National Comprehensive Cancer Network.

C. McNeil, 1999, Journal of the National Cancer Institute.

DNA test for bladder cancer hits a high mark.

C. McNeil, 1996, Journal of the National Cancer Institute.

TCE, designated a known carcinogen, now the focus of ongoing research.

C. McNeil, 2013, Journal of the National Cancer Institute.

NCCN guidelines advocate wider use of colony-stimulating factor.

C. McNeil, 2005, Journal of the National Cancer Institute.

Sentinel node biopsy: studies should bring needed data.

C. McNeil, 1998, Journal of the National Cancer Institute.

In early breast cancer, who does not need chemo? The hunt for prognostic markers.

C. McNeil, 1998, Journal of the National Cancer Institute.

HPV vaccines for cervical cancer move toward clinic, encounter social issues.

C. McNeil, 1997, Journal of the National Cancer Institute.

Two targets, one drug for new EGFR inhibitors.

C. McNeil, 2006, Journal of the National Cancer Institute.

Greying of America will foster new strategies in oncology.

C. McNeil, 1997, Journal of the National Cancer Institute.

Treating chemobrain: rehabilitation therapies emerge.

C. McNeil, 2012, Journal of the National Cancer Institute.

Negative data from lung cancer trial may change practice guidelines, study designs.

C. McNeil, 2006, Journal of the National Cancer Institute.

Monoclonal antibodies progress to the next generation.

C. McNeil, 1995, Journal of the National Cancer Institute.